The objectives of the present work were: to develop and characterize an Sn-2 lipase-labile PD of a c-Myc inhibitor; to demonstrate the stability of the c-Myc-PD in the PFC NPs; to demonstrate the ...
Researchers at Children’s Hospital of Fudan University, Shanghaitech University and Suzhou Zhongke New Drug Incubator Biomedical Technology Co. Ltd. have identified WD repeat-containing protein 5 ...
Expression of the cell cycle inhibitor p15 INK4b is suppressed by the Myc oncoprotein and induced by transforming growth factor-β (TGF-β). The transcription factor Miz-1 activates the Ink4b ...
Hosted on MSN2mon
Jacobio’s KRAS Inhibitor Glecirasib Shows Promising Trial ResultsJacobio Pharmaceuticals announced the publication of data from a registrational clinical trial of their KRAS G12C inhibitor ... RB, and MYC, with the aim of becoming a global leader in drug ...
Activation of MYC is synthetic lethal with IRE1/XBP1 pathway inhibition. We found that inhibition of the IRE1/XBP1 pathway with a highly selective IRE1 RNase inhibitor ORIN1001 suppresses ...
We developed a novel strategy for delivering oncogenic c-Myc inhibitors for targeting melanoma cells. c-Myc prodrugs (PDs) were developed based on Sn-2 phospholipid PDs by coupling 10058-F4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback